

CLAIMS

1. A pharmaceutical composition for glycemic control of a type II diabetic patient, which is prepared for administration before meal and comprises mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, wherein the amount to be administered as a single dose is 5 to 45 mg.
2. A pharmaceutical composition as claimed in claim 1 wherein the composition is prepared for administration just before meal.
3. A pharmaceutical composition as claimed in claim 1 or 2 wherein the composition is to be administered three times a day before each meal for 4 weeks or more.
4. A pharmaceutical composition as claimed in any of claims 1 to 3 wherein the amount to be administered as a single dose is 5 to 22 mg.
5. A pharmaceutical composition as claimed in claim 4 wherein the amount to be administered as a single dose is 10 to 11 mg and the active ingredient is mitiglinide calcium salt hydrate.
6. A pharmaceutical composition as claimed in any of claims 1 to 5 wherein the dissolution time for 75% release in the first fluid of the Japanese Pharmacopoeia is 20 minutes or less.
7. A pharmaceutical composition as claimed in any of claims 1 to 6 wherein the composition is an agent for prevention or treatment of type II diabetes.
8. A pharmaceutical composition as claimed in claim 7 wherein the type II diabetes is a postprandial hyperglycemia.
9. A use of a pharmaceutical composition as claimed in any

of claims 1 to 6 for glycemic control of a type II diabetic patient.

10. A use of a pharmaceutical composition as claimed in any of claims 1 to 7 for prevention or treatment of type II diabetes.

11. A use as claimed in claim 10 wherein the type II diabetes
5 is a postprandial hyperglycemia.

12. A method for glycemic control of a type II diabetic patient, which comprises administering before meal 5 to 45 mg of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof as a single dose.

10 13. A method for glycemic control as claimed in claim 12 wherein the single dose is 5 to 22 mg.

14. A method for glycemic control as claimed in claim 13 wherein the single dose is 10 to 11 mg and the active ingredient is mitiglinide calcium salt hydrate.

15 15. A method for glycemic control as claimed in any of claims 12 to 14 wherein the type II diabetes is a postprandial hyperglycemia.

16. A method for improvement of postprandial hyperglycemia of a type II diabetic patient, which comprises administering
20 before meal 5 to 45 mg of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof as a single dose.

17. A method for improvement as claimed in claim 16 wherein the single dose is 5 to 22 mg.

18. A method for improvement as claimed in claim 17 wherein
25 the single dose is 10 to 11 mg and the active ingredient is mitiglinide calcium salt hydrate.

19. A method for improvement as claimed in any of claims 12

to 18 wherein the number of doses a day is three.

20. A method for improvement as claimed in claim 19 wherein the treatment period is 4 weeks or more.

21. A use of mitiglinide or a pharmaceutically acceptable salt
5 thereof, or a hydrate thereof for the manufacture of a
pharmaceutical composition as claimed in any claims 1 to 8.